Re: UroToday - Testosterone therapy in men with untreated prostate cancer - Abstract

[Guest guest]

" elhorizonte@... " wrote:

> Testosterone and PCa - An interesting study

>

>http://www.urotoday.com/index.php?option=com_jentlacontent & view=enhanced & id=424\

87 & Itemid=57 & sms_ss=email & at_xt=4d83a4cde915bdaa%2C0

>0

There was a discussion of this by Ed Friedman, who is a professor

who does research in hormonetherapies. He said:

" ... my model predicts long term disaster with this treatment

unless something is done to prevent testosterone from being

converted to estradiol. "

See:

http://groups.google.com/group/alt.support.cancer.prostate/browse_thread/thread/\

d675a515c3b76dc6#

[Guest guest]

El Horizonte wrote:

> Sorry everyone is having trouble accessing the link on

> Testosterone replacement that I posted. ...

Here's another way to see the abstract using PubMed.

http://www.ncbi.nlm.nih.gov/pubmed/21334649

[Guest guest]

http://www.urotoday.com/index.php?option=com_jentlacontent & view=enhanced & id=42487 & Itemid=57 & sms_ss=email & at_xt=4d83a4cde915bdaa%2C0

Testosterone therapy in men with untreated prostate cancer - Abstract Thursday, 17 March 2011 Men's Health Boston, Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

A history of prostate cancer has been a longstanding contraindication to the use of testosterone therapy due to the belief that higher serum testosterone causes more rapid prostate cancer growth. Recent evidence has called this paradigm into question. In this study we investigate the effect of testosterone therapy in men with untreated prostate cancer.

We report the results of prostate biopsies, serum prostate specific antigen and prostate volume in symptomatic testosterone deficient cases receiving testosterone therapy while undergoing active surveillance for prostate cancer.

A total of 13 symptomatic testosterone deficient men with untreated prostate cancer received testosterone therapy for a median of 2.5 years (range 1.0 to 8.1). Mean age was 58.8 years. Gleason score at initial biopsy was 6 in 12 men and 7 in 1. Mean serum concentration of total testosterone increased from 238 to 664 ng/dl (p < 0.001). Mean prostate specific antigen did not change with testosterone therapy (5.5 ± 6.4 vs 3.6 ± 2.6 ng/ml, p = 0.29). Prostate volume was unchanged. Mean number of followup biopsies was 2. No cancer was found in 54% of followup biopsies. Biopsies in 2 men suggested upgrading, and subsequent biopsies in 1 and radical prostatectomy in another indicated no progression. No local prostate cancer progression or distant disease was observed.

Testosterone therapy in men with untreated prostate cancer was not associated with prostate cancer progression in the short to medium term. These results are consistent with the saturation model, ie maximal prostate cancer growth is achieved at low androgen concentrations. The longstanding prohibition against testosterone therapy in men with untreated or low risk prostate cancer or treated prostate cancer without evidence of metastatic or recurrent disease merits reevaluation.

Written by: Morgentaler A, Lipshultz LI, R, Sweeney M, Avila D Jr, Khera M. Are you the author?

Reference: J Urol. 2011 Feb 18. Epub ahead of print. doi: 10.1016/j.juro.2010.11.084

PubMed Abstract PMID: 21334649

UroToday.com Prostate Cancer Section > Sorry everyone is having trouble accessing the link on> Testosterone replacement that I posted. ...Here's another way to see the abstract using PubMed.http://www.ncbi.nlm.nih.gov/pubmed/21334649